Drug interactions for the following drug(s)
Applies to: Maxalt 10 MG Oral Tablet <> Suboxone 2 MG / 0.5 MG Sublingual Tablet
Rizatriptan may decrease the excretion rate of Naloxone which could result in a higher serum level.
Applies to: magnesium oxide 400 MG (magnesium 240 MG) Oral Tablet <> Suboxone 2 MG / 0.5 MG Sublingual Tablet
The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Buprenorphine.
Applies to: Maxalt 10 MG Oral Tablet <> Effexor XR 150 MG (as venlafaxine hydrochloride) 24 HR Extended Release Oral Capsule
The risk or severity of adverse effects can be increased when Venlafaxine is combined with Rizatriptan.
Applies to: Effexor XR 150 MG (as venlafaxine hydrochloride) 24 HR Extended Release Oral Capsule <> Suboxone 2 MG / 0.5 MG Sublingual Tablet
Venlafaxine may decrease the excretion rate of Naloxone which could result in a higher serum level.
Applies to: Levonorgestrel 1.5 MG Oral Tablet <> Suboxone 2 MG / 0.5 MG Sublingual Tablet
The metabolism of Buprenorphine can be decreased when combined with Levonorgestrel.
Note: this does not necessarily mean no interactions exist. Always consult with your doctor or pharmacist.
Applies to: Maxalt 10 MG Oral Tablet <> Suboxone 2 MG / 0.5 MG Sublingual Tablet
Drug1 (rxcui = 213322, name = rizatriptan 10 MG Oral Tablet [Maxalt], tty = SBD). Drug2 (rxcui = 1010608, name = buprenorphine 2 MG / naloxone 0.5 MG Sublingual Tablet [Suboxone], tty = SBD). Drug1 is resolved to naloxone, Drug2 is resolved to rizatriptan and interaction asserted in DrugBank between Naloxone and Rizatriptan. Drug1 is resolved to buprenorphine, Drug2 is resolved to rizatriptan and interaction asserted in DrugBank between Buprenorphine and Rizatriptan.
Applies to: magnesium oxide 400 MG (magnesium 240 MG) Oral Tablet <> Suboxone 2 MG / 0.5 MG Sublingual Tablet
Drug1 (rxcui = 198741, name = magnesium oxide 400 MG Oral Tablet, tty = SCD). Drug2 (rxcui = 1010608, name = buprenorphine 2 MG / naloxone 0.5 MG Sublingual Tablet [Suboxone], tty = SBD). Drug1 is resolved to buprenorphine, Drug2 is resolved to magnesium oxide and interaction asserted in DrugBank between Buprenorphine and Magnesium oxide.
Applies to: Maxalt 10 MG Oral Tablet <> Effexor XR 150 MG (as venlafaxine hydrochloride) 24 HR Extended Release Oral Capsule
Drug1 (rxcui = 213322, name = rizatriptan 10 MG Oral Tablet [Maxalt], tty = SBD). Drug2 (rxcui = 729931, name = 24 HR venlafaxine 150 MG Extended Release Oral Capsule [Effexor], tty = SBD). Drug1 is resolved to venlafaxine, Drug2 is resolved to rizatriptan and interaction asserted in DrugBank between Venlafaxine and Rizatriptan.
Applies to: Effexor XR 150 MG (as venlafaxine hydrochloride) 24 HR Extended Release Oral Capsule <> Suboxone 2 MG / 0.5 MG Sublingual Tablet
Drug1 (rxcui = 729931, name = 24 HR venlafaxine 150 MG Extended Release Oral Capsule [Effexor], tty = SBD). Drug2 (rxcui = 1010608, name = buprenorphine 2 MG / naloxone 0.5 MG Sublingual Tablet [Suboxone], tty = SBD). Drug1 is resolved to naloxone, Drug2 is resolved to venlafaxine and interaction asserted in DrugBank between Naloxone and Venlafaxine. Drug1 is resolved to buprenorphine, Drug2 is resolved to venlafaxine and interaction asserted in DrugBank between Buprenorphine and Venlafaxine.
Applies to: Levonorgestrel 1.5 MG Oral Tablet <> Suboxone 2 MG / 0.5 MG Sublingual Tablet
Drug1 (rxcui = 483325, name = levonorgestrel 1.5 MG Oral Tablet, tty = SCD). Drug2 (rxcui = 1010608, name = buprenorphine 2 MG / naloxone 0.5 MG Sublingual Tablet [Suboxone], tty = SBD). Drug1 is resolved to buprenorphine, Drug2 is resolved to levonorgestrel and interaction asserted in DrugBank between Buprenorphine and Levonorgestrel.
Note: this does not necessarily mean no interactions exist. Always consult with your doctor or pharmacist.